Free tool
FAERS Monitor: Symdeko (Copackaged)
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210491 or its brand name (Symdeko (Copackaged), Ivacaftor, Ivacaftor, Tezacaftor). Reports on generic versions are filed under their own applications.
Reports
5,288
Serious
3,301
62% of reports
Hospitalization
2,899
Death reported
74
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- infective pulmonary exacerbation of cystic fibrosis1,183
- hospitalisation459
- infection352
- cystic fibrosis288
- pneumonia286
- headache214
- cough183
- cystic fibrosis respiratory infection suppression168
- pulmonary function test decreased144
- nausea140
- dyspnoea135
- haemoptysis132
- malaise113
- fatigue102
- nasopharyngitis100
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1,201 |
| 2019 | 3,045 |
| 2020 | 801 |
| 2021 | 88 |
| 2022 | 38 |
| 2023 | 39 |
| 2024 | 39 |
| 2025 | 29 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,871 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 1,183 | 1104.1 | 1041.4 | 1,020,064 |
| cystic fibrosis respiratory infection suppressionSignal | 168 | 922.4 | 781.6 | 124,792 |
| cystic fibrosisSignal | 288 | 218.2 | 194.4 | 58,839 |
| pulmonary function test decreasedSignal | 144 | 135.3 | 114.8 | 18,433 |
| haemoptysisSignal | 132 | 18.9 | 16.0 | 2,214 |
| hospitalisationSignal | 459 | 11.9 | 10.9 | 4,598 |
| infectionSignal | 352 | 9.7 | 8.8 | 2,748 |
| pneumoniaSignal | 286 | 3.5 | 3.1 | 520 |
| coughSignal | 183 | 2.6 | 2.3 | 180 |
| nasopharyngitisSignal | 100 | 2.2 | 1.8 | 62 |
| headache | 214 | 1.4 | 1.2 | 20 |
| malaise | 113 | 1.0 | 0.9 | 0 |
| dyspnoea | 135 | 0.9 | 0.8 | 0 |
| nausea | 140 | 0.7 | 0.6 | 18 |
| fatigue | 102 | 0.5 | 0.4 | 46 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.